HTB homepage • Conference reports • Articles by subject • Subscribe February 2009 Contents Editorial Volume 10 Number 1/2 Jan/Feb 2009 Conference reports 9th International Congress on Drug Therapy in HIV Infection, 9-13 November 2008, Glasgow Summary of antiretroviral studies at Glasgow The Antiretroviral Pregnancy Registry: individual drug safety reports on health of infants exposed to ARVs during pregnancy Initial results from PENTA 11 trial of planned treatment interruption Inflammation and coagulation markers askew in children with higher HIV RNA Dosing of lopinavir/ritonavir in the CHIPS cohort Number needed to treat to harm (NNTH) analysis of impact of underlying cardiovascular factors on risk of abacavir-related heart attack Bone disease and HIV Renal tubule damage with tenofovir despite normal glomerular function 10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 6-8 November 2008, London, UK Report from the 10th IWADRLH by Jacqueline Capeau Report from the 10th IWADRLH by Michael DubĂ© Impact of body changes on the quality of life of HIV-positive treatment-experienced patients: an online community-based survey Antiretrovirals Increased atazanavir dose recommended when used in combination with efavirenz or Atripla in naive patients EMEA approves once-daily darunavir/ritonavir (800mg/100mg) for treatment-naive patients in Europe Maraviroc safety label changes included with US traditional approval US approval of paediatric abacavir EMEA supports extension of D:A:D study until at least 2012 and the new remit to include non-AIDS cancers and kidney disease Applications to approve non-refrigerated ritonavir submitted to EMEA and FDA Treatment access Lost benefit of ARVs in South Africa PK and drug interactions Elvitegravir with tipranavir/ritonavir or darunavir/ritonavir Serum bilirubin increases when PEG-interferon and ribavirin are used with atazanavir Drug interactions with integrase inhibitors Drug interactions between efavirenz and itraconazole Effect on tacrolimus when switching from nelfinavir to fosamprenavir Cure-related research Cause for caution on HIV cure report Basic science and immunology Low-level HIV replication versus latency: identifying the source of viral rebounds during treatment interruption Other news Martin Delaney, leading treatment activist and founder of Project Inform, dies at 63 Report refutes HIV denialist claims on childrens HIV trials International AIDS Conference to be held in the US after over 20-year ban Changes at the European Medicines Agency (EMA) On the web 39th Union World Conference on Lung Health Management of hepatitis B: consensus statement and data review PLoS medicine and PLoS clinical trials PDFs Volume 10 Number 1/2 Jan/Feb 2009 PDF HTB homepage • Conference reports • Articles by subject • Subscribe